Navigation Links
The Deal Names Abbott Top Dealmaker for Third Consecutive Year
Date:9/20/2010

The Deal Names Abbott Top Dealmaker for Third Consecutive Year -- ABBOTT PARK, Ill., Sept. 20 /PRNewswire-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Magazines, Publishing & Information Services, Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Awards Click to view news release full screen  

The Deal Names Abbott Top Dealmaker for Third Consecutive Year

   

Awards Recognize Industry-Leading Companies That Demonstrate Effective Strategic Use of Mergers and Acquisitions Over Past Three Years

ABBOTT PARK, Ill., Sept. 20 /PRNewswire-FirstCall/ -- The Deal magazine has named Abbott (NYSE: ABT) as one of its Most Admired Corporate Dealmakers for the third consecutive year.  The Deal honored Abbott as its Most Admired Dealmaker in pharma/biotech for the most effective and consistent use of acquisitions and divestitures since January 2007.  

Over the past 24 months, Abbott has successfully executed on a number of strategic acquisitions that have enhanced the company's diversity, geographic reach and pipeline, and positioned the company for leadership in new, fast-growing markets.  Recently, the company completed its acquisition of Piramal Healthcare Solutions, bringing immediate market leadership in India, the world's second-fastest growing pharmaceutical market.  

"Abbott is honored to again be recognized by The Deal for our track record of acquisitions," said Miles D. White, chairman and chief executive officer, Abbott.  "In 2010, Abbott has successfully executed on a series of transactions to establish a leading presence in emerging markets, enhance its pharmaceutical pipeline and capitalize on global growth opportunities to drive continued top-tier performance."

In 2010, Abbott has:

  • Acquired Solvay Pharmaceuticals, complementing and diversifying its pharmaceutical portfolio and expanding Abbott's presence in key global emerging markets.
  • Purchased Facet Biotech, adding innovative oncology and neuroscience compounds to existing research expertise.
  • Announced a licensing agreement with Zydus Cadila to promote a portfolio of pharmaceutical products in 15 high-growth emerging markets.
  • Acquired a novel investigational biologic compound to treat chronic pain, enhancing Abbott's early-stage pharmaceutical pipeline.
  • Announced a collaboration with Neurocrine and Pierre Fabre to develop and commercialize treatments for endometriosis and oncology, respectively.

  • The Deal's readers rated Abbott best on the award criteria: choice of targets and strategy; price paid (or received) compared to value; execution, including integration; and overall quality of the deal team.  Companies considered for the survey have a market capitalization of $5 billion or more as of Dec. 31, 2009, closed the highest number and value of transactions and generated the largest increase in market capitalization over a three-year period ended Dec. 31, 2009.  

    About The Deal LLCThe Deal LLC (www.TheDeal.com) is a diversified media and information company. We report, analyze and disseminate business and financial news and data that offer fresh insights on the deal economy, a set of interrelated activities, focused on dealmaking of all kinds, whose purpose is to generate corporate and capital growth in a continually changing global market. We serve the global deal community – corporate and financial dealmakers, advisers and institutional investors – with The Deal Pipeline, a transaction information service, and The Deal magazine, a business and financial magazine, website and event brand. The Deal LLC, a privately held company, is owned by private investment funds sponsored by Wasserstein & Co. LP.  

    About AbbottAbbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.  The company employs nearly 90,000 people and markets its products in more than 130 countries.  

    Abbott's news releases and other information are available on the company's Web site at www.abbott.com.


    '/>"/>

    SOURCE Abbott
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Intarcia Therapeutics Names Kurt Graves Executive Chairman to Advance Strategic Interests and Broaden Commercial Goals
    2. FierceBiotech Names VentiRx Pharmaceuticals as One of the Fierce 15 Biotech Companies of 2010
    3. Windhover Information Names D-Tagatose One of Top 10 Most Promising CV/Metabolic Drugs in Development
    4. FierceBiotech Names Obesity Company Gelesis to Fierce 15 List of Top Emerging Biotech Companies
    5. AAIPharma Services Corp. Names Patrick Walsh Chief Executive Officer
    6. INC. 5000 Names ClinixMIS for Third Time
    7. SL Industries Names Louis J. Belardi Chief Financial Officer
    8. BayCare Health System Names Tim Thompson Chief Information Officer
    9. Watson Names Sigurdur Oli Olafsson Executive Vice President, Global Generics
    10. K-V Pharmaceutical Names Thomas McHugh Chief Financial Officer
    11. Ikaria® Names New Chief Financial Officer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/23/2017)... Im Rahmen seiner Schlüsselwachstumsstrategie arbeitet die Guian ... Provinz Guizhou, 2017 mit dem Angebot von Anreize schaffenden Strategien ... einer eingebetteten Hightech-Schlüsselindustrie. Foto - http://mma.prnewswire.com/media/471342/First_CRH__CHina_Railway_High_Speed__Train_Enters_Guian.jpg ... ... ...
    (Date:2/23/2017)... Research and Markets has announced the addition of the "Fibromyalgia ... offering. ... latest research Fibromyalgia Drugs Price Analysis and Strategies - 2016, provides ... The research answers the following questions: ... attributes? How are they positioned in the Global Fibromyalgia market? ...
    (Date:2/23/2017)... Feb. 23, 2017 Regulus Therapeutics Inc ... and development of innovative medicines targeting microRNAs, today announced ... financial results on Thursday, March 2, 2017 after the ... call and webcast on March 2, 2017 at 5:00 ... year 2016 financial results and provide a general business ...
    Breaking Medicine Technology:
    (Date:2/24/2017)... , ... February 24, 2017 , ... The narrative in ... Erik Schanssema ’s true account of his paramedic experiences. Schanssema describes the tragedies ... and his attempts to overcome them. , Schanssema, initially unsure of the career ...
    (Date:2/24/2017)... ... February 24, 2017 , ... The International Association of ... “Imagine Me Beyond What You See” body image mannequin art competition. Selected from 15 ... showcased and the winner revealed at the 31st annual iaedp Symposium, March 22 – ...
    (Date:2/24/2017)... ... 2017 , ... Congratulations to Head Over Heels’ elite gymnast ... Ms. Esparza qualified into this prestigious status after winning the Vault, Floor, ... Nevada. Frida is one of approximately 25 gymnasts in the nation who earns ...
    (Date:2/23/2017)... ... ... The 89th Academy Awards will be celebrated this weekend, which means it’s also ... We invite you to enjoy our 11th annual tongue-in-cheek “salute” to the shoddiest think ... American Progress (CAP), for its report, Lessons From State Performance on NAEP: Why Some ...
    (Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... Los Angeles-based ... episodes of WE TV’s “Mama June: From Not to Hot,” which will begin airing ... “Mama” June Shannon, known to millions from the 2012 reality television series, “Here Comes ...
    Breaking Medicine News(10 mins):